# A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small 

Source: https://onco.cc/trials/nct06606847/  
OnCo record `nct06606847` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Oleclumab, Durvalumab in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.

## Summary

A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA) is a phase 2 interventional study registered as NCT06606847 by AstraZeneca, with 30 participants enrolled, started 2024-09-24 and due to reach its primary completion in 2026-05-04. Interventions recorded: Oleclumab, Durvalumab. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06606847
- Phase: 2
- Setting: A Phase II, Open-label, Multicentre, Single-arm Study of Durvalumab Plus Oleclumab in Patients With Locally Advanced, Unresectable Non-small Cell Lung Cancer Who Have Not Progressed Following Definitive, Platinum-Based Chemoradiation Therapy (LADOGA)
- Sponsor: AstraZeneca
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT06606847: https://clinicaltrials.gov/study/NCT06606847

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Durvalumab](https://onco.cc/drugs/durvalumab/), [Oleclumab](https://onco.cc/drugs/oleclumab/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct06606847.json